Grifols, S.A.-Product Pipeline Review-2015

Grifols, S.A.-Product Pipeline Review-2015

  • Products Id :- GMDHC07007CDB
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Grifols, S.A.-Product Pipeline Review-2015


Global Markets Direct's, 'Grifols, S.A.-Product Pipeline Review-2015', provides an overview of the Grifols, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grifols, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Grifols, S.A. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Grifols, S.A.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Grifols, S.A.'s pipeline products

Reasons To Buy

Evaluate Grifols, S.A.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Grifols, S.A. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Grifols, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Grifols, S.A. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grifols, S.A.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Grifols, S.A. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Grifols, S.A. Snapshot 5

Grifols, S.A. Overview 5

Key Information 5

Key Facts 5

Grifols, S.A.-Research and Development Overview 6

Key Therapeutic Areas 6

Grifols, S.A.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Grifols, S.A.-Pipeline Products Glance 13

Grifols, S.A.-Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Grifols, S.A.-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Phase 0 Products/Combination Treatment Modalities 16

Grifols, S.A.-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Grifols, S.A.-Unknown Stage Pipeline Products 18

Unknown Products/Combination Treatment Modalities 18

Grifols, S.A.-Drug Profiles 19

albumin (human) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

ARD-3150 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

immune globulin (human) 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Recombinant A1PI 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Human Plasmin 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

fibrinogen concentrate (human) 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ARD-3100 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Human Coagulation Factor-VIII (Recombinant) 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Recombinant Plasmin 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Grifols, S.A.-Pipeline Analysis 33

Grifols, S.A.-Pipeline Products by Target 33

Grifols, S.A.-Pipeline Products by Route of Administration 34

Grifols, S.A.-Pipeline Products by Molecule Type 35

Grifols, S.A.-Pipeline Products by Mechanism of Action 36

Grifols, S.A.-Recent Pipeline Updates 37

Grifols, S.A.-Dormant Projects 43

Grifols, S.A.-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

Grifols, S.A., Key Information 5

Grifols, S.A., Key Facts 5

Grifols, S.A.-Pipeline by Indication, 2015 8

Grifols, S.A.-Pipeline by Stage of Development, 2015 9

Grifols, S.A.-Monotherapy Products in Pipeline, 2015 10

Grifols, S.A.-Partnered Products in Pipeline, 2015 11

Grifols, S.A.-Partnered Products/ Combination Treatment Modalities, 2015 12

Grifols, S.A.-Phase III, 2015 13

Grifols, S.A.-Phase II, 2015 14

Grifols, S.A.-Phase I, 2015 15

Grifols, S.A.-Phase 0, 2015 16

Grifols, S.A.-Preclinical, 2015 17

Grifols, S.A.-Unknown, 2015 18

Grifols, S.A.-Pipeline by Target, 2015 33

Grifols, S.A.-Pipeline by Route of Administration, 2015 34

Grifols, S.A.-Pipeline by Molecule Type, 2015 35

Grifols, S.A.-Pipeline Products by Mechanism of Action, 2015 36

Grifols, S.A.-Recent Pipeline Updates, 2015 37

Grifols, S.A.-Dormant Developmental Projects,2015 43

Grifols, S.A., Other Locations 44

Grifols, S.A., Subsidiaries 45

List of Figures

Grifols, S.A.-Pipeline by Top 10 Indication, 2015 7

Grifols, S.A.-Pipeline by Stage of Development, 2015 9

Grifols, S.A.-Monotherapy Products in Pipeline, 2015 10

Grifols, S.A.-Pipeline by Top 10 Target, 2015 33

Grifols, S.A.-Pipeline by Top 10 Route of Administration, 2015 34

Grifols, S.A.-Pipeline by Top 10 Molecule Type, 2015 35

Grifols, S.A.-Pipeline Products by Top 10 Mechanism of Action, 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Grifols, S.A.; Grifols, S.A. - Key Therapeutics; Grifols, S.A. - Pipeline Overview and Promising Molecules; Grifols, S.A. - News; Grifols, S.A. - Latest Updates; Grifols, S.A. - Pipeline; Grifols, S.A. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102135
Site License
USD 3000 INR 204270
Corporate User License
USD 4500 INR 306405



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]